Event info
Date:05 Oct
Time:11:00 - 14:30
Venue:Online
Contact person
Nicole Mastrell

Nicole Mastrell

Event Manager & PA to CEO

nm@mva.org

+45 6141 8634

Preclinical Immuno-oncology Models: Humanized Immune System Mice and Beyond

Join us for a three-hour virtual workshop featuring the leading scientists in the field of immuno-oncology (IO) discussing the best practices of applying humanized immune system (HIS) mice for IO therapies.

Taconic will host three distinct sessions covering topics focused on the use of HIS mice in evaluating efficacy of a wide-range of IO therapeutic modes. We will highlight those models most appropriate for studies involving particular human immune cell types, and review best practices for the use of humanized mouse models in preclinical IO drug discovery research.

 

Date: Tuesday, 5 October 2021
Time: 11:00 a.m. – 2:30 p.m. CEST
Venue: Online

 

READ MORE & SIGN UP

 

Program

Session 1: Introduction of HIS Mouse Models for Preclinical IO Research

 

11:00Welcome & Housekeeping
11:05 – 11:30Utility of Humanized Immune System Mice for The Investigation of Immune Cell Populations and Immunotherapies
Presented by Dr. Ivan Gladwyn-Ng, Taconic Biosciences Field Application Scientist, Taconic Biosciences

 

Session 2: Utility of Humanized Immune System Mice for the Investigation of T and Myeloid Immune Cell Populations and Immunotherapies

 

11:30Engraftment of Patient Derived Xenografts on a New Generation of Humanized Mice
Presented by Dr. Jens Hoffman, Experimental Pharmacology & Oncology Berlin-Buch GmbH
12:05Activation of The ISR Confers Vulnerability to Mitoribosome-Targeting Antibiotics in Melanoma Cells
Presented by Dr. Eleonora Leucci, Katholieke Universiteit Leuven
12:40Break
 12:55Characterization of Humanized Immune System Mice as Pre-clinical Models of Immune Modulatio
Presented by Dr. Mike Oropallo, Merck Sharp & Dohme
13:30Humanized Mice to Evaluate T-cell Based Immunotherapies Against Cancer
Presented by Dr. Christine Sedlik, Institut Curie

 

Session 3: Current and Evolving Approaches to Preclinical IO Models

 

14:05Roundtable discussion
14:30Closing Remarks

 

Organized by